Target intelligence / Profile preview

Long intergenic non-protein coding RNA 466 (LINC00466)

Target
LINC00466
Molecular classification
Long non-coding RNA, intergenic non-coding RNA, lncRNA, lincRNA
01

Overview

Long intergenic non-protein coding RNA 466 (LINC00466) is a long non-coding RNA (lncRNA) that does not encode a protein but instead regulates the expression of other genes through post-transcriptional mechanisms. Most notably, LINC00466 acts as a molecular sponge for specific microRNAs, such as miR-493 and miR-137, affecting the availability and regulatory effects of these microRNAs on their mRNA targets. LINC00466 is upregulated in various tumors, such as glioma, tongue squamous cell carcinoma, and lung adenocarcinoma, where it promotes cancer cell proliferation, migration, invasion, and resistance to apoptosis—partly by upregulating oncogenic proteins (such as HMGA2 and PPP1R14B) by sequestering their regulatory microRNAs. Elevated LINC00466 expression has been associated with poor prognosis in some cancer types and may potentially serve as a biomarker or a component of targeted cancer therapy, though it is not a direct molecular drug target in the sense of classical receptors, enzymes, or transporters[1][2][3][4].

Other names
LINC00466long intergenic non-protein-coding RNA 00466
02

Mechanism of action

Competes for binding to microRNAs (ceRNA mechanism, acting as a molecular sponge); indirectly regulates gene and protein expression downstream of sponged miRNAs (e.g., HMGA2 via miR-493[1], PPP1R14B via miR-137[2])

03

Biological functions

Regulation of gene expressionmolecular sponge for microRNAs (e.g., miR-493, miR-137)modulation of cell proliferationmigrationinvasionpromotion of apoptosis inhibition
04

Disease associations

Cancer (glioma, tongue squamous cell carcinoma, lung adenocarcinoma)Other
05

Safety considerations

None established for direct targeting; therapeutic modulation might impact cancer cell proliferation, migration, or resistance but no specific safety risks documented
06

Interacting drugs

Temozolomide (modulates sensitivity of glioma cells to TMZ)
07

Biomarkers

Elevated LINC00466 may serve as a prognostic biomarker in some cancers (e.g., shorter survival in tongue squamous cell carcinoma with high expression)

Beyond the preview

Go deeper on Long intergenic non-protein coding RNA 466 (LINC00466).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Long intergenic non-protein coding RNA 466 (LINC00466).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call